In vivo experiments were performed to determine whether the cross-linking of membrane immunoglobulin (mlg) D on mature B cells, in the absence of T cell help, leads to B cell death. Mice were injected with either a monoclonal antibody (mAb) that cross-links mlgD effectively or a mAb that binds to mlgD avidly but cross-links it to a limited extent, and effects on B cell number and B cell Ia, mlgM, and mlgD expression were observed. In most experiments, mice were pretreated with anti-interleukin 7 mAb to prevent the generation of new bone marrow B cells, and with anti-CD4 mAb to prevent the generation of T cell help. In some experiments, mice also received anti-Fc3,RII mAb to prevent cross-linking of mlgD with Fc'yRII, and cobra venom factor to prevent possible mlg-complement receptor interactions and complement-mediated T he two-signal theory of B lymphocyte activation predicted that an interaction between antigen and B cell membrane immunoglobulin (mlg) 1 would trigger a B cell-activating event that would lead, in the presence of additional signals, to clonal expansion and antibody production, but, in the absence of additional signals, to death (1). Since this theory was proposed, the cross-linking orB cell mlg has been shown to costimulate B cell proliferation and differentiation in the presence of such stimuli as T cell-produced cytokines (2, 3) and T cell membrane costimulatory molecules (4, 5), while the cross-linking of mlg on newly generated B cells has been shown to lead to B cell unresponsiveness and death (6-8). The ultimate effects of mlg cross-linking on mature B cells, in the absence of additional stimuli, have, however, been less well defined. Cross-linking of mlg, in the absence of T cell help, stimulates enhanced B cell expression of receptors involved in proliferation and cellular interactions (9-11) and, under some conditions, can stimulate DNA synthesis, al-1 Abbreviations used in this paper: GerMS, affinity-purified goat anti-mouse IgD antibody; HEL, hen egg lysozyme; HNA, HBSS supplemented with 10% newborn bovine serum and 0.2% sodium azide; mlg, membrane immunoglobulin. though clonal expansion and antibody secretion are not induced (12-16). It is not known, however, whether these activated B cells eventually return to a resting state, survive but become anergic, or die. This issue has been difficult to resolve in vitro, where unstimulated B cells have a short life span and start to undergo apoptosis within 24 h (17). Study of the effects of mlg cross-linking on B cell life span has also been difficult, in part because of a long-standing controversy about whether resting B cells live for a long or short time in vivo (18) (19) (20) (21) (22) . Recent experiments that have either labeled dividing B cells and B cell precursors in vivo (21) or used antibodies to IL-7 to prevent the in vivo generation of new B cells (22) have provided compelling evidence that most mature B cells have a life span that is measurable in weeks, rather than days. This conclusion has made it reasonable to question whether the cross-linking of B cell mlg, in the absence of additional signals, shortens that life span. To investigate this, we have injected mice with anti-IgD antibodies, including two rat IgG2a anti-IgD mAbs that bind to IgD with similar avidity but differ considerably in their abilities to cross-link mlgD and activate B cells in a T cell-independent fashion (23). In most of these experiments, the generation of new B cells was blocked by pretreating mice with anti-IL-7 mAb (22), and the generation of T cell help was blocked by pre-515
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though clonal expansion and antibody secretion are not induced (12) (13) (14) (15) (16) . It is not known, however, whether these activated B cells eventually return to a resting state, survive but become anergic, or die. This issue has been difficult to resolve in vitro, where unstimulated B cells have a short life span and start to undergo apoptosis within 24 h (17) . Study of the effects of mlg cross-linking on B cell life span has also been difficult, in part because of a long-standing controversy about whether resting B cells live for a long or short time in vivo (18) (19) (20) (21) (22) . Recent experiments that have either labeled dividing B cells and B cell precursors in vivo (21) or used antibodies to IL-7 to prevent the in vivo generation of new B cells (22) have provided compelling evidence that most mature B cells have a life span that is measurable in weeks, rather than days. This conclusion has made it reasonable to question whether the cross-linking of B cell mlg, in the absence of additional signals, shortens that life span. To investigate this, we have injected mice with anti-IgD antibodies, including two rat IgG2a anti-IgD mAbs that bind to IgD with similar avidity but differ considerably in their abilities to cross-link mlgD and activate B cells in a T cell-independent fashion (23) . In most of these experiments, the generation of new B cells was blocked by pretreating mice with anti-IL-7 mAb (22) , and the generation of T cell help was blocked by pre-treating mice with anti-CD4 mAb (24) . In addition, in some experiments, potential complement-mediated killing of B cells and potential inhibitory interactions between mlg and Fc'yRII were blocked by treating mice with cobra venom factor (25) and anti-FcyRII mAb (26) , respectively. The results of these experiments demonstrate that anti-IgD antibody treatment under these conditions causes B cells to die over a 2-to 7-d period, defines differences in the susceptibility of different B cell populations to the lethal effects of anti-IgD mAbs, and shows that T cell help can prevent cell death.
Materials and Methods
Mice. Female BALB/c mice were purchased from the Small Animals Division of the National Cancer Institute (Frederick, MD) and were used at age 8-14 wk.
Immunological Reagents. 
Results
Treatment with Anti-IL-7 mA b Blocks the Development of New B Lymphocytes. Our procedure for evaluating the in vivo effects of mlgD cross-linking on B cell survival depended, in many experiments, on blocking the production of new B cells that might replace B cells that die. For this reason, studies were initially performed to confirm the effectiveness of the technique used to prevent B cell production in these experiments. BALB/c mice were injected intraperitoneaUy with 3 mg of m25 anti-IL-7 mAb three times a week for 2 wk. Mice were then killed, their spleen and bone marrow cells stained for mlgM and B220, and dual parameter flow microfluorimetry was used to determine percentages of bone marrow and spleen cells that expressed B220 and/or mlgM. Anti-IL-7 mAb treatment decreased the percentage of bone marrow cells that had the pre-B cell phenotype (B220+IgM -) by "~85% and the number of immature B cells (B220auUlgM +) (22, 35) to a barely detectable level (Fig. 1) . The percentage of bone marrow B lymphocytes that had a more mature phenotype (B220bnshqgM +) was much less affected by anti-IL-7 mAb treatment ( Fig. 1) , and the number of splenic B ceils was not significantly affected (data not shown). These observations confirmed the demonstration by Grabstein et al. (22) that depletion of IL-7 prevents B cell generation and that mature B cells have a relatively long in vivo life span, and validated the use of anti-IL-7 mAb-treated mice as a closed system in which B cell loss would not be compensated for by the generation of new, bone marrow-derived, B cells. mlgD Cross-linking Causes B Cell Death 
In Vivo Treatment with Anti-IgD mAbs Causes Increased Ia Expression by Both IgM a`I~ and IgMb'~ ~' Spleen Cells and Decreased mlgM Expression by lgM d"zl Spleen Cells.
To determine the initial effects on splenic B cell populations of injecting mice with anti-IgD mAbs, spleen cells were obtained from anti-IL-7 mAb-treated mice that had been injected I d before killing with either 11-26 (a rat IgG2a mAb that binds IgD avidly but ineffectively cross-links IgD) or HB86 (a rat IgG2a mAb that cross-links mIgD effectively) (23) . Mice were also treated with anti-CD4 mAb (to prevent T cell help), and, in some experiments, with anti-Fc3,RII mab (to block interactions between antibody-bound mlgD and the B cell Pc3' receptor that might negatively signal B cells [36, 37] ) and cobra venom factor (to prevent the possibility of complement-mediated killing of B cells and interactions between mlgD and B cell complement receptors) (38, 39) . Spleen cells from treated and control mice were counted, then stained for mlgM and either B220 or Ia a, and analyzed by flow microfluorimetry. Treatment with either anti-IgD mAb had no effect on IgM expression by IgMbng h' B cells but considerably decreased mlgM expression by IgM a~u B cells ( whether they received anti-Fc7IklI mAb and cobra venom factor. To determine if the persistence of IgMb~g h~ spleen cells in anti-IgD mAb-treated mice might reflect decreased mlgD expression by mlgM~ ht spleen cells compared with mlgM au~ spleen cells, spleen cells from mice treated with anti-IL-7, anti-CD4, and anti-Fc3,RII mAbs, plus cobra venom factor, were stained with FITC-anti-IgM mAb, Cy5-anti-B220 mAb, and biotin-anti-IgD mAb (FF1-4D5), followed by streptavidin-R-PE. Stained cells were fixed and analyzed for IgD-associated fluorescence on B220+IgM a~ll and B220+IgMbng ht cells. While IgM a~ spleen cells were almost uniformly mlgDbng ht, IgMbng ht spleen cells contained a majority IgDb~g ht population and a minority IgD a~ll population (Fig. 5) . Inasmuch as the entire population of IgMbag h' spleen cells is maintained in anti-IgD mAb-treated mice, this result indicates that resistance to the B cell-depleting effect of anti-IgD mAb treatment is not simply a result of decreased mlgD expression.
Anti-IgD mAb Treatment Causes the Selective Loss of lgM d"tt
To determine the kinetics of B cell loss in response to injection of anti-IgD mAb, mice were treated with anti-ILo7, anti-CD4, and anti-Fc'yRII mAbs, as well as cobra venom factor, and killed before or 1-5 d after injection of HBt~6. Numbers of IgM a~ll and IgMb~ig ht spleen cells were determined by cell counting and flow microfluorimetric analysis after staining for mlgM and B220. No significant loss of IgMb~g h~ spleen cells was detected during the course of the experiment, and no loss of IgM d~t spleen cells was detected during the first 24 h after HBt~6 injection (Fig. 6) . The number of IgM d~n spleen cells, however, decreased significantly by 2 d after HBt~6 injection and continued to decrease, at a relatively constant rate, during the next 3 d. IgD Fluorescence Intensity 
Anti-IgD mAb Treatment Selectively Causes the Loss of mlgM dull Pe@heral Lymph Node Cells. The selective loss of
IgM a~ll cells from the spleen might represent selective destruction of these cells, selective migration of these cells to another organ, or loss of both IgM a"u and IgMbns ht spleen cells that is accompanied by acquisition of increased mlgM by some IgM an" cells. To distinguish among these possibilities, we examined the effects of anti-IgD mAb injection on IgM a~" and IgMb~is ~t peripheral lymph node cells. The peripheral lymph node B cell population differs from that of the spleen in that very few IgMbrig ht cells are normally present (33) . Thus, if treatment with anti-IgD mAb caused some initially IgM a~ll spleen cells to become IgMbng ht, then the percentage of IgM b~gh~ lymph node cells would be expected to increase in anti-IgD mAb-treated mice. Instead, 5 d after mice that had been pretreated with anti-IL-7, anti-CD4, and anti-Fcj'RII mAbs, as well as cobra venom factor, were injected with HB~6, we observed a four-to fivefold decrease in the percentage of IgM a~ll lymph node cells, with little change in the percentage of IgM b~ight lymph node cells (Fig. 7) . As was observed with spleen, the effects of injection of 11-26 were qualitatively similar, but considerably less marked than those induced by HB66. The observation that anti-IgD mAbs have the same effects on peripheral lymph node B cells as on splenic B cells suggests that the selective loss of IgM a~ll spleen ceils in anti-IgD mAb-injected mice is not a result of expression of increased mlgM by some IgM a~n cells and rules out the possibility that anti-IgD mAb causes the migration of IgM a~]l spleen cells to peripheral lymph nodes. merit or injected with 10, 33, or 100/zg of HB~56. These mice were killed 1 d after anti-IgD mAb injection. A second set of mice was treated with the same reagents, as well as with anti-IL-7 mAb, and killed 5 d after HBc56 injection. Injection of 33 or 100 #g of HB/$6 caused a three-to fourfold decrease in the number of splenic IgM d"ll cells 5 d after HB86 injection, while injection of 10 #g of HBc56 had only a minor effect on the number of these cells (Fig. 8, right) .
Low Doses of Anti-lgD mAb Do Not Cause the Loss of Splenic
Although the injection of 10, 33, or 100 #g of HB~56 substantially decreased B cell mlgD expression and increased B cell Ia expression 1 d later (Fig. 8, left 
T Cell Help Decreases the Anti-IgD Antibody-induced Loss of lgM't"ll B Cells and Induces the Appearance of an Ia+B220 -
IgM-Cell Population. To investigate whether the generation of T cell help during the course of an immune response could prevent anti-IgD antibody-induced loss of splenic B cells, mice were treated with anti-IL-7 and anti-Fc'yRII mAbs plus cobra venom factor and either anti-CD4 mAb or an isotype-matched control mAb 01.2). Mice were then injected with GotM~5, which is a stronger inducer of T cell help than HBc56, and killed 7 d later. Immunofluorescence staining and flow microfluorimetry were used to determine mlgM expression by B220 § and Ia § spleen cells from these mice, and from mice that received no GotMS. GotMc5 treatment caused an ,o40% decrease in spleen cell number in anti-CD4 1000 m U . anti-IL-7 mAb, anti-Fc3,RII mAb, cobra venom factor, and either anti-CD4 mAb or an isotype-matched control mAb, then injected intravenously with 800 #g of Gc~MS. Mice were killed 7 d after GotM8 injection, and spleen cell suspensions were prepared, counted, and stained with FITC-anti-B220 and biotin-anti-lgM mAbs or FITC-anti-l-A a and biotin-anti-lgM mAbs, followed in all cases by streptavidin-K-PE. A FACScan | was used to determine percentages of B220 + and la d+ IgM dull and IgMbrig ht spleen cells. Means and standard errors are shown.
mAb-treated mice and an ~50% increase in spleen cell number in T cell-sufficient mice (Fig. 9, top) . In anti-CD4 mAb-treated mice, GotM~ caused a greater than fivefold decrease in the number of IgM a"n spleen cells and a two-to threefold decrease in the number of IgMbrig ht spleen cells (Figs. 9 and 10 ). In contrast, in T cell-sufficient mice, GotM~ caused a less marked decrease in the number of B220* IgM d~11 and B220+IgMbrig ht spleen cells (Fig. 9 , middle, and Fig. 10, lower left) and induced the appearance of a large population of Ia + spleen cells that lack B220 and express little or no mlgM (Fig. 9, middle, and Fig. 10 , compare lower left and right panels). This latter population probably corresponds to the large population of Ia + B220-IgM-IgG-secreting spleen cells that are present at this time in GotMSinjected T cell-sufficient mice (26, 40) .
Discussion
Our experiments demonstrate that anti-IgD mAbs cause a substantial decrease in the number of IgM a"ll spleen and lymph node B cells when injected into mice in which the generation of new B cells and T cell help are blocked by anti-IL-7 and anti-CD4 mAbs, respectively. It is likely that B cell loss in these mice results from cell death, rather than migration of B cells from the spleen and lymph nodes to other IgM Fluorescence Figure 10 . T cell help prevents the loss of splenic B cells in anti-lgD antibody-injected mice. Representative fluorescence histograms of stained spleen cells from the same experiment depicted in Fig. 8 are shown. Solid lines are histograms of B220+ or Iaa+ spleen cells stained with biotin-amiIgM mAb followed by streptavidin-R-PE; dotted lines are histograms of the same cells stained with streptavidin-R-PE in the absence ofbiotin-antiIgM mAb.
organs or a change in B cell phenotype, because (a) anti-IgD antibody also causes loss of mature B cells from the bone marrow; (b) histologic studies of lung and liver from antiIgD antibody-treated mice fail to show increased lymphoid infiltrates (data not shown); (c) parallel decreases are observed in numbers of Ia + and B220 + cells; and (d) no increase in the number of mlgG * cells is seen (data not shown). The consequences of the interaction of mlgD and anti-IgD mAb in our model should resemble those that follow an interaction between antigen and the mlg of an antigen-specific B cell. Features of IgG antibodies that differentiate them from most antigens, such as complement fixation and interaction with Fc receptors, cannot account for the induction of B cell death in our system, inasmuch as (a) rat IgG2a mAbs, which were used for most of our experiments, have little ability to directly kill targeted cells in vivo (41) , and, at least in rats, do not bind to FcTRI (42) (Figs. 9 and  10 ). These same considerations suggest that death is likely to occur by apoptosis. Increased numbers of apoptotic B ceils have not been observed in anti-IgD mAb-injected mice (Ashman, R., personal communication), however, presumably because the slow progression of cell death in this system, coupled with rapid in vivo removal of apoptotic cells, prevents the accumulation of detectable numbers of apoptotic cells. The failure to detect apoptotic lymphocytes in vivo when the rate of cell death is slow has also been noted by other investigators (43, 44) .
The slow loss of B cells in this system resembles that described recently in double-transgenic mice, in which B cells express mlgM and mlgD specific for hen egg lysozyme (HEL) and HEL is present in serum (45) . B cells in these doubletransgenic mice are anergic (45) and have an in vivo half-life of ~5 d, while the half-life of HEL-specific B cells in transgenie mice that do not have serum HEL is ~4 wk (46) . The double-transgenic study differs from ours in that B cell loss was measured indirectly, by determining percentages of B cells that have synthesized DNA during a defined period of time, rather than by directly recording decreases in B cell numbers. This methodological difference may be important, because the half-life of anergic, HEL-specific B cells was considerably longer when measured in the same study by a cell transfer technique (46) , although it was still shorter than that of competent HEL-specific B cells. In addition to differences in the methodology used to determine B cell life span, our studies differ from investigations with double-transgenic mice in that antigen-specific B cells in the double-transgenic mice become exposed to antigen as soon as they. have acquired mlg, while the 2-wk pretreatment with anti-IL-7 mAb before injection of anti-IgD mAb in our system allows newly generated B cells to mature before mlgD is cross-linked. Thus, while the results in these two systems appear to be consistent, our observations demonstrate that the decrease in B cell life span that results from signaling through mlg does not require that this signaling start when B cells are immature, even though immature B cells have been shown to be more easily killed or tolerized than mature B cells by exposure to antigen or anti-Ig antibody (6) (7) (8) . Results that are consistent with ours have been obtained in a variant of the double-transgenic system in which HEL-specific B cells that were initially exposed to a subtolerogenic concentration of HEL during their development still became anergic if exposed to a higher HEL concentration after they had matured, and in an experiment in which the transfer of HEL-specific B cells to an HEbexpressing mouse caused the donor B cells to become anergic (47) . Although it was not determined whether the anergic B cells in these double-transgenic studies had a decreased in vivo life span, a likely interpretation of all of the double transgenic studies, when combined with ours, is that Ig cross-linking, in the absence of additional signals, inactivates and eventually deletes most autoreactive B cells, regardless of whether autoreactivity results from expression of germline or somatically mutated Ig genes.
In addition to methodological differences and differences in time of exposure to ligand for mlg, our system and the double-transgenic system differ in that HEL interacts with both mlgM and mlgD in the double-transgenic mice, while only mlgD is cross-linked in anti-IgD antibody-injected mice. Signaling through mlgM has been reported to be more effective than signaling through mlgD at inducing the growth arrest of B cell tumor lines that resemble immature B cells (48, 49) . Furthermore, the removal of mlgD from mature B cells has been reported to make them easier to tolerize than mlgD-expressing B cells by exposure to antigen (50) (51) (52) , and B cells from mice that lack a functional c5 chain gene are more easily tolerized by in vitro antigen exposure than are B cells from conventional mice (53) . In contrast, experiments with transgenic mice that expressed either IgM or IgD anti-HEL on their B cells as well as serum HEL or a cell membranebound form of HEL demonstrated that either mlg isotype can transduce signals that lead to B cell anergy or clonal abortion, respectively (54) . In addition, B cells from conventional mice are stimulated in vitro to rapidly apoptose by extensive cross-linking of either mlgM or mlgD with biotinylated antiIgM or anti-IgD mAbs and avidin (55) . Our studies now establish that the in vivo interaction of a soluble ligand with mlgD on fully mature B cells can decrease the B cell's life span to that characteristic of anergic B cells.
Our studies, combined with previous in vivo and in vitro experiments, suggest that the difference between B cell anergy and clonal abortion is quantitative rather than qualitative. Relatively limited mlg cross-linking, as is induced by a mAb such as [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] or an antigen such as HEL, decreases B cell life span to a relatively limited extent, which cannot be demonstrated in vitro and is not easily observed in vivo unless the generation of new B cells is blocked (46) . More extensive mlg cross-linking, as is induced by a mAb such as HB~56, reduces B cell life span to a greater extent. Still more extensive mlg cross-linking, as would be induced by cells that express multiple plasma membrane representations of the epitope that is recognized by B cell mlg, can abort the development of epitope-specific B cells (7, 56) and cause B cells specific for that epitope to apoptose within a 24-h period (57) . For practical purposes, this would mean that B cells specific for self-antigens, for which T cell help is not available, would have their half-life shortened in proportion to the extent to which their mlg is cross-linked by self-antigens. Increased antigen valency and concentration, and higher affinity of the mlg on a B cell clone for that antigen, would increase the extent of mlg cross-linking and the limitation of B cell life span. As a result, autoreactive B cells that could cause the greatest threat to health by avidly binding antigens that are abundantly present on cell membranes would be eliminated most rapidly, while lower avidity binding, binding of less abundant antigen, and binding of nonpolymeric antigen would be associated with a less profound decrease in B cell life span that might allow less threatening autoreactive B cells to still be stimulated by a foreign antigen. Because elimination of all B cells that are even slightly autoreactive might eliminate cells that are required for optimal antibody responses to foreign pathogens, a continuous inverse relationship between extent of autoreactivity and B cell life span may represent the optimal compromise between preventing autoimmune disease and allowing maximal protective antibody responses to foreign pathogens.
The results of our experiments also provide evidence that not all populations of mature B cells are equally susceptible to negative signaling through mlg. The mature IgMbng ht B cell population, which includes marginal zone B cells (58, 59) , is retained to a much greater extent in mice injected with anti-IgD mAbs than is the more predominant mlgM aull B cell population, which predominantly consists of mantle layer B cells (58, 59) . The resistance of IgMbrig ht B cells to the cytocidal effects of anti-IgD mAb does not reflect an absence of mlgD from these cells or an inability of anti-IgD antibody to signal these cells. Many mature mlgMbng ht B cells express considerable quantities ofmlgD (Fig. 8) , and the mAb 11-26, which cross-links mlgD poorly, is actually more effective at inducing increased Ia expression by IgMb=g ~t than IgM duu spleen cells. These observations suggest that, although the cross-linking of mlg induces stimulatory signals for both IgMbng ht and IgM auu B cells, the signals that are generated may not be identical in these two B cell subsets, and/or IgMbng ht B cells may be more resistant to the induction of cell death by the signals that are generated. Inasmuch as splenic polysaccharide-reactive B cells are predominantly in the splenic marginal zone B cell population (60, 61) , and polysaccharide antigens generally express multiple representations of a given epitope and are unable to induce antigen-specific T cell help (62, 63) , the ability of IgMb=g h~ B cells to resist the tolerogenic effects of mlg cross-linking in the absence of T cell help may contribute to the generation of antipolysaccharide antibody responses. The resistance of IgM baght B cells to killing by cross-linking of their mIg, however, appears to be relative rather than absolute: the injection of mice with GoeM/~, which should have a greater ability than anti-IgD mAbs to cross-link mIgD, causes the loss of a considerable percentage of IgM bright B cells when the generation of T cell help has been blocked (Figs. 8 and 9 ).
The induction of T cell help in mice injected with antiIgD antibody both maintains the survival of most mlgM d~u B calls and stimulates the generation of a large number of B cells that exhibit a phenotype (Ia+B220-mIgM-) that is typical of newly generated IgG-secreting cells (16, 40 
